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&p.1:Abstract Classically, neoplasia has been considered to
be primarily a disturbance in the regulation of prolifera-
tion, but it is now clear that programmed cell death is
dysregulated as well as proliferation. The genes that are
implicated in the regulation of these processes, such as
p53, c-myc and bcl-2, are often also altered in neo-
plasms. We have studied proliferation and programmed
cell death in hyperplastic polyps, adenomas, carcinomas
in adenomas and adenocarcinomas of the colorectum, us-
ing the MIB-1 antibody which recognizes the Ki-67 pro-
liferation related antigen, and an in situ nick-end label-
ling procedure for histochemical labelling of proliferat-
ing and apoptotic cells. In addition, immunohistochemis-
try was used to study the expression of the p53, c-myc
and bcl-2 proteins. The material studied consisted of 12
samples of normal mucosa, 8 hyperplastic polyps, 39 ad-
enomas with different degrees of dysplasia and including
3 that carried a carcinoma, and 10 adenocarcinomas, all
formalin fixed and paraffin embedded. The Ki-67 index
indicated that proliferation increased progressively in hy-
perplasia, through different degrees of dysplasia in ade-
noma, to reach the highest level (Ki-67 index of 50%) in
adenocarcinoma. Apoptosis also increased in hyperplas-
tic polyps and in adenomas, but decreased significantly
in adenocarcinomas. p53 Labelling was seen in 77% of
the carcinomas but in only 3% of the adenomas. Expres-
sion of c-myc increased in adenomas and carcinomas.
Furthermore, a shift from predominantly nuclear to pre-
dominantly cytoplasmic expression was seen in progres-
sive neoplasms. Expression of bcl-2 was increased in an
occasional hyperplastic polyp, but was increased mark-
edly in almost all adenomas. Strikingly, in the adenomas
with a carcinoma, the carcinoma showed weaker bcl-2
expression than the adenoma. In 20% of the carcinomas
some bcl-2 staining was seen but this was less extensive
than in the adenomas. Our findings indicate that in the
progression from adenoma to carcinoma both increased
proliferation and decreased apoptosis occur. This is par-
alleled by an increased expression of p53 and an in-
creased and predominantly cytoplasmic expression of c-
myc, but a decreased expression of bcl-2. This decreased
bcl-2 expression does not lead to an increase in apoptotic
activity.
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Introduction
Cancer has long been regarded as a disorder of prolifera-
tion. It has recently become clear that dysregulation of
programmed cell death may be also involved in the
pathogenesis of neoplasia. In general terms, the volume
increase of a neoplastic cell mass will depend on the net
result of cell production through cell division and cell
loss through apoptosis. The relative contribution of in-
creased cell division or decreased cell loss to the volume
increase of a neoplasm is largely unknown; nor do we
know whether this varies during the different phases of
the process of carcinogenesis.
For the study of the balance between proliferation and
apoptosis the adenoma–carcinoma sequence [1] in the
colorectum provides an attractive model. These lesions
occur frequently, are pathogenetically related and, al-
though longitudinal follow-up studies to validate these
hypotheses are difficult if not impossible to perform,
progression from a premalignant to a malignant phase
proceeds through a series of morphologically well-de-
fined steps. Each of these steps has been fitted into a
model for the molecular genetic sequence of events that
results in colorectal cancer [2].
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The involvement of the oncogene K-ras and of the tu-
mour-suppressor genes p53, APC and DCC in colorectal
carcinogenesis has been well established [3]. Of these
genes, it is clear that p53 is involved in both cell cycle
and apoptosis regulation; the p53 gene appears to be in-
activated in up to 60% of colorectal carcinomas [4]. It
has been shown that the p53 protein can cause cell cycle
arrest but can also stimulate apoptosis, and the hypothe-
sis currently favoured is that genomic damage leads to
up-regulation of p53 expression, which halts the cell cy-
cle to allow DNA repair. When DNA damage is irrepara-
ble, apoptosis is induced by p53 [5].
Other regulators of proliferation and apoptosis are c-
myc and bcl-2 [6, 7]. Elevated levels of c-myc occur in
up to 80% of colorectal cancers [8]. The myc protein is
primarily involved in cell cycle progression, and in the
absence of key growth factors c-myc induces apoptosis.
Bcl-2 expression is upregulated in most colorectal adeno-
mas and also in a proportion of colorectal carcinomas [9,
10]. It is a member of a complex family of apoptosis-reg-
ulating genes [11, 12], which, when up-regulated, pro-
long cell survival through inhibition of apoptosis [13].
Bcl-2 and c-myc have been assumed to cooperate in colo-
rectal carcinogenesis [14].
Analysis of proliferation and apoptosis at the tissue
level has become feasible with the development of tools
that allow visualization of these events in individual
cells. Proliferation can be visualized through immuno-
histochemical staining of nuclear antigens that are ex-
pressed exclusively in cycling cells [15]. Apoptosis can
be visualized using nick end-labelling, which detects the
characteristic internucleosomal DNA strand breaks [16].
In this paper we report on the proliferative and apoptotic
index of normal colorectal mucosa, hyperplastic lesions,
adenomas with varying levels of dysplasia and carcino-
mas (partly in adenomas) of the colorectum. We have
also examined the expression of p53, bcl-2 and c-myc,
genes that play a role in the regulation of proliferation
and apoptosis.
Materials and methods
A series of consecutive cases (concerning 57 lesions from 51 pa-
tients) of hyperplastic polyps (8), adenomas (39) and carcinomas
(10) of the colorectum was retrieved from the files of the Depart-
ment of Pathology, University Hospital, Rotterdam. From all car-
cinoma specimens, normal mucosa from the proximal or distal
margins of resection, which was always more than 5 cm from the
tumour, was taken as control tissue. All specimens had been fixed
in 4% buffered formaldehyde and embedded in paraffin. Histologi-
cal diagnoses were made on routine H&E stained tissue sections,
using standard criteria. Dysplasia in adenomas (15 tubular, 11 tub-
ulovillous, 13 villous) was graded into low (31) and high (8). In 3
adenomas a carcinoma was found.
Expression of p53, the c-myc protein and the Ki-67 prolifera-
tion-associated protein was determined on 5-µm paraffin sections.
After mounting on APES (aminopropyltriethoxysilane, Sigma, St.
Louis, Mo.)-coated slides, the sections were deparaffinized and re-
hydrated. Endogenous peroxidase was blocked by incubation
(15 min, RT) in methanol with 3% H2O2. Antigen retrieval was
performed for all three antigens by microwave treatment (2 cycles
of 5 min at 700 W in a Biorad H2500 oven, in a 0.01 M citrate
buffer, pH 6.0). After cooling (15 min), washing in phosphate buf-
fered saline (PBS, pH 7.0) and preincubation in 10% normal goat
serum (Dako, Glostrup, Denmark, 15 min), the sections were incu-
bated with the primary antibody overnight at 4°C. The anti-p53
was a mouse monoclonal antibody, clone DO7 (Dako), used at a
dilution of 1:50; the anti-Ki-67 was the MIB-1 mouse monoclonal
antibody (Immunotech, Hamburg, Germany) used at a dilution of
1:100; the anti-c-myc was the clone GE10 antibody, raised against
the C-terminal peptide of the human c-myc protein (Oncogene,
New York, N.Y.), diluted 1:3000, the anti-bcl-2 was clone 124
(Dako) diluted 1:50.
After washing in PBS, bound antibodies were visualized using
biotinylated rabbit-anti-mouse Ig (Dako) and the streptavidin–bi-
otin-peroxidase system (Dako). Peroxidase activity was developed
with 3–3’ diaminobenzidine-HCl. The slides were lightly counter-
stained with haematoxylin and mounted.
Apoptosis was visualized through detection of internucleoso-
mal fragmentation of DNA, which was visualized using in situ
nick-end labelling with terminal deoxynucleotidyl transferase
(TdT; TUNEL) [16]. To this end, rehydrated sections were treated
with proteinase K (20 µg/ml in 10 mM Tris-HCl buffer, pH 7.4;
15 min, RT). After washing, the sections were incubated with TdT
(10 U/µl; Gibco) and 0.05 nmol/ul of biotin-16-dUTP (Boehrin-
ger, Mannheim, Germany), 2 h at 37°C. Subsequently the sections
were washed in a citrate–saline buffer and incubated with a strep-
tavidin–biotin peroxidase complex (Dako). As positive control,
tissue sections were pre-treated (60 min) with 1 µg/ml DNA-seI
(Stratagene, USA). Tissue sections incubated without TdT were
used as negative control. Visualization of peroxidase activity was
as for immunohistochemistry.
For counting, normal crypts were divided in three sections with
approximately equal cell numbers. For normal crypts the Ki-67
and TUNEL index were determined by counting 200 and 2000
cells respectively in consecutive crypts. For tumours the Ki-67 and
TUNEL indices were determined by counting 200 and 2000 cells
in consecutive fields, chosen randomly in non-necrotic areas of the
tumours. p53 Staining was regarded as positive when more than
5% of the nuclei showed intense staining. For c-myc, nuclear and
cytoplasmic staining were semiquantitatively graded (negative,
weak, moderate or strong). For bcl-2 staining grading into nega-
tive, focal or positive was used. Student’s t-test for independent
samples was used to assess the significance of the observed differ-
ences. Correlations were analysed using Pearson’s correlation co-
efficient. Statistical significance was taken as P<0.05.
Results
Of the 39 adenomas, 31 showed low-grade dysplasia and
8, high-grade dysplasia. In 3 adenomas an intramucosal
carcinoma was identified. Of the 10 carcinomas, 3 were
well differentiated and 7 moderately well differentiated.
The Ki-67 labelling is illustrated in Figs. 1 and 2, and
the labelling indices in the analysed tissue specimens are
shown in Fig. 3. As expected, the Ki-67 labelling index
decreased from the crypt base (27.7 ± 11.1%) to the lu-
minal surface (0.1 ± 0.1%). In hyperplastic polyps the
mean Ki-67 index (24.5 ± 4.8%) was comparable to that
in the crypt base. Proliferating cells were mainly con-
fined to the lower half of the crypt. In adenomas the Ki-
67 index increased significantly throughout the lesion
and in correlation with the degree of dysplasia
(26.5 ± 8.8% in low-grade vs 34.8 ± 5.8% in high-grade
adenomas, P<0.05). In carcinomas the highest labelling
index (53.1 ± 10.5%) was obtained (P<0.001 vs any oth-
er category).
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The TUNEL labelling is illustrated in Figs. 4 and 5,
and the labelling indices of the analysed specimens are
shown in Fig. 6. The TUNEL index in the normal crypt
increased (from 0.4 ± 0.4% to 2.6 ± 1.3%) towards the
crypt surface. In hyperplastic polyps TUNEL staining
extended downward into the crypts. The TUNEL index
corresponded to that of the mucosal surface. Apoptosis
occurred throughout the lesion in all neoplasms. The
TUNEL index was not higher in low-grade adenomas
(3.9 ± 2.1%), but was significantly higher in high-grade
adenomas (5.6 ± 3.4%, P<0.05). In carcinomas the
TUNEL index was lower (3.1 ± 1.2%) than in high-grade
adenomas, but this difference had only borderline signifi-
cance. In adenomas, a trend towards a positive correla-
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Fig. 1 Ki-67 labelling of an adenoma. Proliferating cells are not
limited to a proliferation zone but are dispersed throughout the le-
sion. ×200 &/fig.c:
Fig. 2 Ki-67 labelling of a carcinoma. ×200 &/fig.c:
Fig. 4 TUNEL labelling of normal colon mucosa. Labelling is
limited to cells at the mucosal surface. ×200 &/fig.c:
Fig. 5 TUNEL labelling of an adenocarcinoma. ×200 &/fig.c:
Fig. 10 Immunoperoxidase staining for c-myc in an adenoma.
×200 &/fig.c:
Fig. 11 Immunoperoxidase staining for c-myc in a carcinoma.
Note that in the adenoma (Fig. 6) the staining is predominantly
nuclear, whereas in the carcinoma predominantly strong cytoplas-
mic staining is observed. ×200 &/fig.c:
tion (P = 0.07) was found between the Ki-67 and
TUNEL labelling indices (Fig. 7). For the group of carci-
nomas no such trend was apparent (data not shown).
Nuclear p53 immunohistochemical staining was
found in 6 of 10 (60%) of the carcinomas as well as in
all 3 carcinomas in adenoma (which makes 9 out of 13
carcinomas, 77%, positive), but in only 1 (high-grade
dysplasia) adenoma. Neither the Ki-67 nor the TUNEL
index was significantly correlated with p53 expression
(Fig. 8), although both tended to be higher in p53-posi-
tive cases. Expression of p53 was not found in hyper-
plastic polyps or normal mucosa.
As reported previously [17], we found bcl-2 staining
in normal crypt base cells, which appeared to increase in
3 (37%) hyperplastic polyps. Of the adenomas, 85%
were positive either focally or diffusely without any sig-
nificant difference according to the degree of dysplasia.
Of all carcinomas (including the 3 carcinomas in adeno-
ma) 5 (40%) stained for bcl-2, although often weakly.
Notably, the carcinomas in bcl-2 positive adenomas
showed reduced staining. Bcl-2 staining correlated nei-
ther with the Ki-67 index nor with the TUNEL index
(Fig. 9).
Moderate to strong staining for c-myc protein was
found in 62% (24/39) of the adenomas and in 77%
(10/13) of the carcinomas (including the carcinomas in
adenoma; Figs. 10, 11). The staining pattern was pre-
dominantly nuclear in the adenomas. Moderate to strong
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Fig. 3 Ki-67 index in normal mucosa and in hyperplastic and neo-
plastic lesions of the colorectum. Horizontal bars indicate the
mean (normal versus all lesions P<0.001; low-grade and high-
grade adenomas vs carcinomas P<0.001) &/fig.c:
Fig. 6 TUNEL index in normal mucosa and in hyperplastic and
neoplastic lesions of the colorectum. Horizontal bars indicate the
mean (normal vs all adenomas P<0.001; normal vs all carcinomas
P<0.001; high-grade adenomas vs all carcinomas P = 0.07) &/fig.c:
Fig. 7 Relationship between Ki-67 and TUNEL indices in adeno-
mas (u) and carcinomas (l). For adenomas P = 0.07; R = 0.29 &/fig.c:
Fig. 8 p53 Staining in relation to Ki-67 and TUNEL index in co-
lorectal carcinomas. No significant differences are observed &/fig.c:
Fig. 9 Relationship between bcl-2 staining and TUNEL index in
adenomas (u) and carcinomas (l). The differences observed are
not significant &/fig.c:
regulation of the cell cycle often also function in the reg-
ulation of apoptosis [5], with p53 and c-myc as exam-
ples. Up-regulation of p53 expression occurs subsequent
to genome damage, which leads to cell cycle arrest to al-
low for DNA repair to take place. Irreparable damage,
however, leads to p53-mediated apoptosis.
Expression of the c-myc protein is normally seen ear-
ly in the G1 phase of the cell cycle, and up-regulation of
c-myc expression without a concurrent growth factor
stimulus leads the cell to undergo apoptosis [18]. The
regulation of apoptosis appears to be a complex process
involving many genes; one of the first of these to be rec-
ognized as apoptosis regulator was bcl-2, which encodes
for an apoptosis blocking protein [13]. It has subsequent-
ly been shown that bcl-2 is member of a family of apop-
tosis regulators, which also includes bax, bcl-x and bak
[11, 12]. The balance between cell production through
proliferation and cell loss through apoptosis determines
how fast a tumour grows and, consequently, the balance
between regulators of proliferation and apoptosis is an
important determinant of tumour behaviour. The aim of
the present study was to document proliferative and apo-
ptotic activity in benign, premalignant and malignant
disorders of growth in the colorectum and to correlate
these with the expression of regulators of apoptosis. To
visualize proliferation and apoptosis we chose Ki-67 la-
belling and TUNEL, both of which are accepted standard
techniques for this type of analysis. The reliability of our
histochemical findings was assessed by comparing our
results with those previously reported by other groups
[19–22]. Our TUNEL labelling patterns of normal muco-
sa correspond closely to those of Sträter et al. [19], and
proliferation and apoptosis indices correspond closely to
those of Tsujitani et al. [20]. The indices reported by
Baretton et al. [21] are somewhat lower, but these au-
thors considered only TUNEL-positive cells that showed
additional morphological features of apoptosis, which
might account for the difference. We excluded necrotic
areas from our TUNEL analyses to avoid over-estimation
due to false positive labelling of necrotic cells.
As expected, apoptotic activity was inversely correlat-
ed with proliferative activity in the normal colon. Apo-
ptotic cells were found almost exclusively on the luminal
surface of the mucosa. The proliferative activity of hyper-
plastic polyps corresponded with that of the normal crypt
base whereas the apoptotic activity corresponded with
that of surface epithelial cells. Neither was limited to the
crypt base but also occurred closer to the lumen. These
findings indicate that for the development of hyperplastic
polyps, a phase of increased proliferation may be respon-
sible, which is almost but not completely balanced by in-
creased apoptosis. The proliferative activity increased in
adenomas with high-grade dysplasia; low-grade dysplas-
tic adenomas displayed a proliferative activity that corre-
sponded to that of hyperplastic polyps. A corresponding
increase in apoptotic activity was found in colorectal ade-
nomas. The highest proliferative activity occurred in the
carcinomas. Strikingly, in the carcinomas a trend towards
a reduction in apoptotic activity was found.
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Fig. 12 Semiquantitative evaluation of staining for c-myc in rela-
tion to Ki-67 labelling. With increasing Ki-67 index c-myc stain-
ing shows a shift from predominantly nuclear to predominantly
cytoplasmic (P<0.001; R = 0.52; N exclusively nuclear staining,
N>C more nuclear than cytoplasmic staining, N = C equal nuclear
and cytoplasmic staining, N<C more cytoplasmic than nuclear
staining, C exclusively cytoplasmic staining &/fig.c:
cytoplasmic c-myc staining was found in 33% (13/39) of
the adenomas and in 77% (10/13) of the carcinomas.
When all neoplasms were taken together a strong corre-
lation between high predominantly cytoplasmic c-myc
staining and Ki-67 index was found (Fig. 12). Nuclear c-
myc staining correlated neither with the Ki-67 nor with
the TUNEL index.
Discussion
Most colorectal carcinomas are assumed to develop from
colorectal adenomas through gradual accumulation of
multiple genetic defects [2]. Some of these involve genes
whose product plays a role in tissue homeostasis. For a
long time the emphasis in models of carcinogenesis has
been concentrated almost exclusively on increased cell
proliferation. It has become well established, however,
that decreased apoptotic cell loss also plays a significant
part [18, 19]. Remarkably, genes that have a role in the
Bedi et al. [22] studied apoptosis in the adenoma–car-
cinoma sequence using a slightly different technique and
also found apoptosis to be reduced in carcinomas. Tsuji-
tani et al. [20] compared the carcinoma component with
the adenoma component in carcinomas in adenoma and
also found decreased apoptosis in the carcinomas in
combination with increased proliferative activity. These
findings, in line with earlier observations [23, 26], indi-
cate that adenomas arise primarily through increased
proliferative activity, which is only partly compensated
for by the rate of apoptosis, though it does rise in adeno-
mas. The presumably higher growth rate of carcinomas
relative to adenomas may be partly due to a decreased
rate of apoptosis. Tatebe et al. [27] recently investigated
apoptosis and proliferation in primary and metastatic co-
lon cancers. For primary carcinomas their findings corre-
spond well with ours. An interesting observation in their
study is an increased proliferation rate in lymph nodes
and liver metastases, together with a relatively greater in-
crease in apoptotic activity, suggesting a relatively higher
cell loss and consequently a lower growth rate in meta-
static tumours.
To clarify the role of apoptosis-regulating genes, we
compared proliferation and apoptosis indices with the ex-
pression of p53, bcl-2 and c-myc. We found p53 expres-
sion in 10 of 13 (77%) of the carcinomas (including the 3
carcinomas in adenoma), but in only 1 (3%) adenoma. In
the carcinoma group, p53 and proliferation index were
not correlated. There was a strong correlation (P<0.0001)
when adenomas and carcinomas were pooled, but this can
be accounted for by the low rate of p53 positivity and the
generally lower proliferation index in adenomas. There
was a trend for apoptosis to be increased in p53-positive
carcinomas but this was not statistically significant. Bcl-2
expression in colorectal adenomas and carcinomas has
been previously reported [9, 10, 14, 17, 28–31]. Hague et
al. [28] and Sinicrope et al. [14] reported bcl-2 staining in
over 60% of colorectal carcinomas. Our data, which have
already been reported [17], are in agreement with those of
Scott et al. [29] and Kaklamanis et al. [30] and indicate
that relative to colorectal adenomas, colorectal carcino-
mas show a reduction in bcl-2 expression. Given the
function of bcl-2 as apoptosis suppressor and the de-
creased rate of apoptosis in colorectal carcinomas this
paradox is not easy to explain. It has become clear, how-
ever, that the regulation of apoptosis is complex and in-
volves not only bcl-2 but also a variety of other members
of this gene family [11, 12], in addition to other regulat-
ing genes, including p53 and c-myc. This might imply
that carcinomas acquire other genetic lesions, which
render bcl-2 redundant [29]. Bcl-2 expression was not
correlated with p53 expression, as reported previously
[29]. When adenomas and carcinomas were taken togeth-
er, a strong negative correlation was found between pro-
liferative activity and bcl-2 expression.
Our results regarding the expression of c-myc are
similar to those of earlier reports [31, 32]. In normal and
hyperplastic mucosa c-myc staining was limited to crypt
base cells. Increased c-myc immunoreactivity was found
in a combination of nuclear and cytoplasmic staining in
77% of the neoplasms. Staining was more frequently nu-
clear in adenomas but cytoplasmic in carcinomas. This
probably accounts for the positive correlation we found
between cytoplasmic c-myc staining and the proliferative
index. No correlation was found between bcl-2 staining
and c-myc staining. Earlier reports have documented in-
creased c-myc staining with advanced Dukes stage and
shortened disease-free survival and decreased c-myc ex-
pression with cellular differentiation [31, 32]. Overall,
these data suggest that in the progression of colorectal
neoplasms increased c-myc expression occurs with a
preferentially cytoplasmic pattern. Although c-myc is a
nuclear phosphoprotein, the cytoplasmic staining pattern
in cancer is unlikely to be an artefact, because it can be
produced with several antibodies, as has been reported
repeatedly. As suggested by Mooy et al. [33], the cyto-
plasmic distribution might be due to (undefined) protein
alterations.
In conclusion, in hyperplastic polyps of the colon and
rectum an almost balanced increase in proliferation and
apoptosis is found, with a mostly normal pattern of ex-
pression of the apoptosis-regulating genes p53, bcl-2 and
c-myc. In the adenoma–carcinoma sequence a continuous
increase in proliferative activity is found, whereas apop-
tosis tends to decrease in carcinomas. A corresponding
pattern of bcl-2 expression indicates that bcl-2 is not the
sole regulator of apoptosis in colorectal neoplasms. In the
adenoma–carcinoma sequence c-myc expression gradual-
ly increases with a shift towards a cytoplasmic pattern.
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